FDA adverse event reports on statin-associated rhabdomyolysis

Annals of Pharmacotherapy

Volumn 36, Issue 2, 2002, Pages 288-295

  Omar, Mohamed A ^a   Wilson, James P ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Adverse events; Drug interactions; HMG CoA reductase inhibitors; Hyperlipidemia; Myopathy; Rhabdomyolysis; Spontaneous reporting; Statins

Indexed keywords

'FRACTAL'; ANTIFUNGAL AGENT; APLACTIN; ATORVASTATIN; BRISTACOL; CARDIOL; CERIVASTATIN; CHLORZOXAZONE; COLEMIN; CYCLOSPORIN; DIGOXIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPAXAN; LIPEMOL; LIPLAT; LIPOFREN; LIPONORM; LYMETEL; MACROLIDE; MEDOSTATIN; MEVINOLIN; MEVLOR; MIBEFRADIL; NEFAZODONE; NERGADAN; NICOTINIC ACID; PANTOK; PRASTEROL; PRAVA; PRAVASELECT; PRAVASTATIN; PRIMESIN; REDUCOL; SELECTIN; SELIPRAN; SIMVASTATIN; SIVASTIN; TACROLIMUS; TAUCOR; TECNOLIP; TOTALIP; UNCLASSIFIED DRUG; WARFARIN; XARATOR;

ARTICLE; DATA BASE; DRUG FATALITY; DRUG SURVEILLANCE PROGRAM; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERLIPIDEMIA; PRIORITY JOURNAL; RHABDOMYOLYSIS; TREATMENT OUTCOME;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTILIPEMIC AGENTS; FEMALE; HUMANS; MALE; RHABDOMYOLYSIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0036163750     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1A289     Document Type: Article

References (35)

1. Spontaneous reporting in the United States
2. Editorial. Risk management of marketed drugs: FDA and the interface with the practice of medicine
3. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
4. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations [Lipoprotein and Coronary Atherosclerosis Study (LCAS)]
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
6. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS)
7. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
8. A review of clinical trials comparing HMG-CoA reductase inhibitors
9. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: A reappraisal
10. Comparative review of the adverse effects of treatments for hyperlipidemia
11. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia
12. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
13. Drug interactions and the statins
14. Efficacy and tolerability of simvastatin (MK-733)
15. Safety, tolerability, and efficacy of simvastatin and fenofibrate - A multicenter study
16. Current perspectives on statins
17. Interactions with hydoxylmethylglutaryl-coenzyme A reductase inhibitors
18. Rhabdomyolysis with simvastatin use
19. Rhabdomyolysis: A review of the literature
20. Rhabdomyolysis: A comprehensive guide
21. Rhabdomyolysis and HMG-CoA reductase inhibitors
22. Statin-fibrate combination therapy
23. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
24. Drug utilization study methodologies: National and international perspectives
25. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs
26. False-positives in spontaneous reporting: Should we worry about them?